NBTXR3
2 abstracts
Abstract
Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Johns Hopkins Medicine, University of Chicago, Nanobiotix,
Abstract
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Moffitt Cancer Center, Johns Hopkins Medicine, Nanobiotix,